Skip to search formSkip to main contentSkip to account menu

Emitefur

Known as: 3-((3-(Ethoxymethyl)-5-fluoro-3,6-dihydro-2,6-dioxo-1(2H)-pyrimidinyl)carbonyl)benzoic acid, 6-(benzoyloxy)-3-cyano-2-pyridinyl ester, 3-[3-(6-Benzoyloxy-3-cyrano-2-pyridyloxycarbonyl)benzoyl]-1-(ethoxymethyl)-5-fluorouracil, 3 (3-(6-benzoyloxy-3-cyano-2-pyridyloxycarbonyl)benzoyl)-1-ethoxymethyl-5-fluorouracil 
An orally available antimetabolite composed of the 1-ethoxymethyl derivative of 5-fluorouracil (5-FU) and the dihydropyrimidine dehydrogenase (DPYD… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

Antineoplastic AgentsFluorouracil

Narrower (1)

BOF A2
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2000
2000
Phase I assessment of the pharmacokinetics, metabolism, and safety of emitefur in patients with refractory solid tumors.
PURPOSE To determine the toxicities, dose-limiting toxicities (DLT), maximum-tolerated dose, and pharmacokinetic profile of… 
2000
2000
A Phase II Trial of a New 5-Fluorouracil Derivative, BOF-A2 (Emitefur), for Patients with Advanced Gastric Cancer
Abstract The antineoplastic effects of BOF-A2 (Emitefur), a 5-fluorouracil (5-FU) derivative, in capsule form were assessed in… 
Review
1999
Review
1999
Oral fluoropyrimidines: a closer look at their toxicities.
Patient preferences, quality of life issues, and economic considerations are driving the development of orally administered… 
1997
1997
104 Phase II study of emitefur (BOF-A2) in advanced non-small cell lung cancer (NSCLC)
1996
1996
Leukopenia-inducing effect of a combination of a new 5-fluorouracil (5-FU)-derived drug, BOF-A2 (emitefur), with other 5-FU-derived drugs or BV-araU (sorivudine) in rats.
BOF-A2 (emitefur: 3-(3-[6-benzoyloxy-3-cyano-2-pyridyloxycarbonyl]benzoyl)-1-ethoxy- methyl-5- fluorouracil), a novel 5-FU (5… 
1996
1996
619Combined effect of clinically relevant doses of emitefur, a new 5-fluorouracil derivative, and radiation in murine tumors
1994
1994
Efficacy of a new 5-fluorouracil derivative, BOF-A2, in advanced non-small cell lung cancer. A multi-center phase II study.
Oral BOF-A2 (Emitefur), a new derivative of 5-fluorouracil (5-FU) containing both 1-ethoxymethyl-5-FU (EMFU), a masked form of 5… 
1994
1994
Toxicity study of emitefur, a new anitineoplastic agent (IV); 52-week oral toxicity study in rats
1994
1994
Reproductive and developmental toxicity studies of emitefur, a new antineoplastic agent. II: Teratology study in rats with oral administration
1993
1993
Emitefur (BOF-A2)のマウス免疫能に及ぼす影響
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)